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ABSTRACT 
Acetyl-CoA carboxylase beta, encoded by the ACAB gene, plays an important role in the oxidation 
of fatty acids. The aim of this study was to check the hypothesis that allelic variants of ACACB 
influence the risk of obesity and type 2 diabetes mellitus.  
Twenty five tagging single nucleotide polymorphisms (SNPs) capturing common variants of the 
ACACB gene were selected and analyzed in two cohorts including 1695  postmenopausal women of 
the general population and in 161 women with severe obesity (BMI >35). In vitro binding of 
transcription factors was explored by electrophoretic mobility shift assays (EMSA). T alleles at the 
rs2268388 locus were overrepresented in women with severe obesity (18% vs. 10% in controls; OR 
1.74 [95% confidence interval 1.30-2.47]), which was statistically significant after multiple-test 
adjustment (p=0.0004). Likewise, T alleles at the rs2268388 locus and C alleles at the rs2239607 
locus were associated with diabetes, in the discovery as well as in the replication cohorts, even after 
women with severe obesity were excluded (OR 3.6 and 2.8, for TT and CC homozygotes, 
respectively). Allelic differences in the binding affinity for nuclear proteins were revealed in vitro by 
EMSA and competition experiments were consistent with the binding of glucorticoid receptor and 
serum response factor. 
In conclusion, common polymorphisms of ACACB gene are associated with obesity and, 
independently, with type 2 diabetes in postmenopausal women, suggesting that the activity of acetyl-
CoA carboxylase beta plays an important role in these disorders related to energy metabolism. 
KEYWORDS: ACACB, obesity, type 2 diabetes, polymorphisms 
 3 
 
1. INTRODUCTION 
Obesity and type 2 diabetes mellitus are two prevalent disorders in western countries, with a well 
known relationship between them [1]. Obesity constitutes a major risk factor for the development of 
diabetes and it is always associated with insulin resistance [2]. As many common disorders, diabetes 
and obesity have an important genetic component. Genome-wide studies have identified several loci 
related to these disorders [3-7], but those loci only explain a small fraction of the disease risk, and in 
many cases do not identify the causal variants [8;9], suggesting that most of the genes involved and 
the functional variants remain to be identified in further investigations. 
It is well recognized that changes in fatty acid metabolism, particularly fatty acid oxidation, play an 
important role in the development of insulin resistance. Skeletal muscle from obese people is less 
able to oxidize fat [10], which is exacerbated in the skeletal muscle of patients with type 2 diabetes 
[11;12]. The metabolism of insulin-resistant skeletal muscle appears to favor fat synthesis rather than 
fat oxidation [13]. The imbalance between fatty acid synthesis and fatty acid oxidation further 
increases lipid accumulation within the cytoplasm of skeletal muscle cells, which would turn these 
cells even more resistant to insulin. 
Acetyl-CoA carboxylase (ACAC) catalyzes the synthesis of malonyl-CoA, a key molecule in fatty 
acid metabolism. In humans, there are two ACAC isoforms, ACACA and ACACB, encoded by 
genes located in chromosomes 17 and 12, respectively. Whereas ACACA is predominantly expressed 
in the liver and adipose tissue, the heart and skeletal muscle are the major tissues expressing 
ACACB. It has been suggested that ACACA plays a major role in fatty acid synthesis, whereas 
ACACB is preferentially involved in fatty acid oxidation [14;15]. Thus, ACACB is an appealing 
candidate gene for obesity and diabetes, which are characterized by an impaired fat oxidation. 
Therefore, the aim of this study was to test the hypothesis that allelic variants of the ACACB gene 
are associated with obesity and/or diabetes.  
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2. MATERIALS AND METHODS 
2.1. Study subjects and genotyping 
The discovery cohort included 972 Caucasian postmenopausal women from the general population 
(mean age 66; range 47-88) taking part in epidemiologic studies about mineral metabolism and 
cardiovascular risk [16;17]. All were living in Cantabria, a small region in Northern Spain and 
provided informed consent. Women with non-Spanish ancestors were excluded.    
The severe obesity group included 161 female patients, 50-81 years of age, from the obesity 
outpatient clinic, with BMI above 35 kg/m2. Patients with metabolic disorders causing secondary 
obesity were excluded. BMI varied between 35.1 and 62.4 kg/m2  (table 1). 
We selected tagging SNPs covering the common variation of the ACACB gene with Tagger software 
using the following parameters: minor allele frequency (MAF) of 10%, capture threshold of r2 >= 
0.8, and a maximum tagging distance of 200 kb. For comparison purposes, the rs1121980 
polymorphism of the FTO gene was also studied, as it has been associated with obesity in several 
studies [18]. DNA was isolated from peripheral blood by using standard procedures and quantified 
with the Qubit system (Invitrogen). SNPs were analysed by iPlex technology on a Mass-Array 
platform (Sequenom, Germany).   
SNPs showing phenotypic associations in the discovery cohorts were also analyzed in the Valencia 
cohort. This replication cohort included 723 Caucasian postmenopausal women aged 45-82 years 
attending a menopause clinic and living in Valencia, a Mediterranean region in Eastern Spain.  
Patients with type 2 diabetes were identified according to the 2003 ADA criteria [19]. Patients with 
type 1 diabetes or secondary diabetes were not included in the study cohorts. 
2.2. In silico analysis of transcription factor binding 
For investigating if the nucleotide changes might result in changes in the binding of transcription 
factors, we carried out an in silico analysis of the surrounding sequence (plus and minus 30 
nucleotides), by using MattInspector and MAPPER search tools [20;21].  
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2.3. Electrophoretic mobility shift assays 
Nuclear extracts were prepared from sub-confluent HepG2 cell cultures as previously reported [22]. 
For rs2268388, 27-nt long double-stranded oligonucleotides, with the sequence  
GGCAGAGAACACTC[C/T]GTTTCCTGCCCA were used. The  rs22399607  specific 
oligonucleotide had the sequence GGCCCCTGATA[C/T]GTTAGGCTATAA.  They were labeled 
in 5’with IRDye®680 (Tecknochrom). The gel bands were analyzed in an ODYSSEY infrared 
imaging system (Li-Cor Biosciences, Lincoln, NE). The relative affinity of each allele was analysed 
by competing it with increasing amounts of the unlabelled allele which had shown a stronger 
binding. The bands were quantified and the affinities were calculated by representing the inverse of 
band intensity versus the excess of unlabelled oligonucleotide. A higher slope indicated lower 
oligonucleotide-protein affinity. Competition experiments were carried out using oligonucleotides 
containing the consensus binding sequences for the glucocorticoid receptor  
(ATTACTAGAACATCCTGTACAGTCGAC) or the serum response factor  
(TACACAGGATGTCCATATTAGGACATC) [23;24] . 
 
2.4. Statistical analysis 
The HWE was tested with Plink software. Haplotypic blocks were constructed with Haploview, 
using the Gabriel method [25]. The associations of alleles and genotypes with BMI, obesity and 
diabetes were tested with Plink [26]. Since BMI distribution was skewed, the statistical analysis was 
performed with log-transformed values. Haplotype analyses was performed using a 2- or 3-SNP 
sliding window. Power estimates were obtained with Quanto software (available at 
http://hydra.usc.edu/gxe/). The power of the study to detect a locus associated with disease in the 
discovery cohort was 68% and 99%, for odds ratio (OR) of 1.5 and 2, respectively, if the minor 
allele frequency was higher than 10 %. Similarly, it had 87% and 99% power to detect a locus 
explaining at least 1% and 2%, respectively, of the variance of a quantitative trait such as BMI. The 
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multiple test threshold for significance was estimated with the method of Li and Ji, as implemented 
in the SnpSpd web tool [27], which takes into consideration the linkage disequilibrium between loci. 
The estimated number of independent tests was 14, resulting in a multiple test-adjusted significance 
threshold of 0.0037. To obtain a combined estimate of the genotype-phenotype associations in the 
discovery and replication cohorts, the Maentel-Haenszel adjusted ORs were calculated using Epidat 
software (available at http://www.sergas.es/MostrarContidos_N3_T01.aspx?IdPaxina=62713).  
 
 
3. RESULTS 
3.1. Association of ACACB polymorphisms with adiposity 
The characteristics of women studied are shown in table 1. 
One of the 26 SNPs selected was excluded because of genotyping technical problems (rs4766587); 3 
other SNPs were excluded because questionable HWE, with uncorrected p-values <0.05 (table 2). 
The haplotypic block structure is shown in figure 1. 
The single locus analysis did not reveal significant associations of ACACB polymorphisms with BMI 
in the general population. Likewise, no association was found between the FTO polymorphism and 
BMI. However, in the whole study group (general population and women with severe obesity 
together), rs2268388 genotypes were significantly associated with BMI  (p=0.0043), almost reaching 
the 0.0037 threshold for significance after correction for multiple tests. T alleles were associated 
with higher BMI. The mean BMI values in women with TT, TC and CC genotypes were 34.1±8.4, 
32.0±11.9 and 30.4±7.2 kg/m2, respectively. The haplotypic analysis confirmed the results but did 
not increase the strength of association (not shown), and the haplotypic conditional analysis revealed 
that rs2268388 was the only independent contributor to the association. There were marked 
differences between the genotype frequencies in the general population and in women with severe 
obesity: T alleles were overrepresented in the severe obesity population (18%, versus 10% in 
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controls; OR 1.74 [95% confidence interval 1.30-2,47], p=0.0004) (table 3). The significance of the 
association was below the multiple test adjusted threshold and the association was quantitatively 
similar to that found with the rs1121980 polymorphism of the FTO gene (OR 1.56 [95% CI 1.23-
1.97], p=0.00026) (figure 2). Similar results were found in the haplotypic analysis (not shown).  
In the Valencia cohort, the rs2268388 was not associated with BMI, thus confirming the lack of 
association between BMI and ACACB allelic variants in the general population. 
3.2. Association of ACACB polymorphisms with type 2 diabetes 
Since obesity is a well-known factor associated with type 2 diabetes, we analyzed the association of 
ACACB  polymorphisms with diabetes mellitus after excluding women with marked elevations of 
BMI (ie, BMI>35). 
We found several polymorphisms within a 14 kb distance of rs2268388 associated with diabetes 
(table 4). The rs2239607 polymorphism, located 3.5 kb downstream of rs2268388, showed the 
strongest association, almost reaching the multiple test-adjusted significance. C alleles were 
associated with higher risk of diabetes. The genotypes frequencies were: CC 7.9%, CT 42.1% and 
TT 50.0% in diabetic patients; and 3.6%, 32.1% and 64.3%, respectively, in non-diabetic women. 
Similar results were obtained when BMI was included as a covariate (table 4). 
Two polymorphisms associated with type 2 diabetes in the discovery cohort were also analyzed in 
the Valencia cohort, rs2268388 and rs2239607.  In this cohort both polymorphisms also showed a 
significant association with type 2 diabetes,  that appeared to fit better a recessive genetic model (p-
values 0.005 and 0.021, respectively).  The risk alleles were the same in both populations (Cantabria 
and Valencia): T alleles at the rs2268388 locus and C alleles at rs2239607 locus.  Thus, when the 
results of both cohorts were combined, in comparison with the most common CC genotype at 
rs2268388, OR for the TT genotype was 3.6, whereas in comparison with the most common TT 
genotype at the rs2239607 locus, OR  for CC genotype was and 2.8 (95% CI 1.4-5.6) (table 5).  
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3.3. Functional analysis of rs2268388 and rs2239607 
The ability of different alleles to bind transcription factors was explored by EMSA. The experiments 
showed that the T-allele oligonucleotide of rs2268388 had higher binding than the C-allele, a result 
confirmed in competition experiments (figure 3). Similar EMSA experiments were carried out with 
oligonucleotides specific for the two alleles of the rs2239607 polymorphism. As shown in the figure 
3, there were allelic differences in nuclear protein binding, with stronger binding to the T-allele 
oligonucleotides.  
The in silico analysis of transcription factor binding sites suggested that the nucleotide change  
altered the affinity of the glucocorticoid receptor (GR) for the sequence including the rs2239607 
polymorphism, as well as the affinity of the Serum Response Factor (SRF), a transcription factor that 
has been associated with insulin response, for the DNA region containing the rs2239607 
polymorphism.  Indeed, competition experiments with a 20-fold excess of an unlabeled 
oligonucleotide known to bind GR displaced the proteins from the labeled rs226388 oligonucleotide, 
suggesting that  GR contributes to the formation of the retarded protein-DNA complex (figure 4). On 
the other hand, competition with an unlabeled oligonucleotide containing the SRF binding site 
completely displaced the proteins from the labeled rs2239607 oligonucleotide, indicating the 
presence of SRF in the complex (figure 4). 
 
4. DISCUSSION 
ACACB encodes one of the major forms of the enzyme catalyzing the synthesis of malonyl-CoA. 
Malonyl-CoA serves both as an intermediate in fatty acid synthesis and as an allosteric inhibitor of 
carnitine palmitoyltranferase 1(CPT1) which regulates the transfer of long-chain fatty acyl-CoAs 
from the cytosol into the mitochondria. The two isoforms of ACAC, ACACA and ACACB, have a 
high degree of sequence identity, the major difference being in the N- terminal domain of ACACB, 
which is known to help the binding to the mitochondrial membrane and regulates local malonyl-CoA 
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levels, CPT1 activity and consequently fatty acid oxidation[10]. The different ability of ACACA and 
ACACB to bind to the mitochondrial membrane, together with their tissue expression patterns, 
suggest that the fate of the malonyl-CoA synthesized is different: while ACACA is preferentially 
involved in fatty acids synthesis, ACACB controls  fatty acid oxidation. In agreement with this, 
ACACA knock out mice, with a markedly impaired ability to synthesize fatty acids, die before birth. 
The effect of ACACB suppression in mice is controversial. Initial reports suggested that null mice  
are leaner than wild type,  mainly due to an increased rate of fat oxidation in both heart and skeletal 
muscle [14;28]. However, those observations have been questioned [29]. 
Further studies are needed to elucidate the actual role of both ACAC forms in lipid metabolism in 
physiological and pathological conditions in different tissues. Nevertheless, the fact that ACACB 
synthesizes the malonyl-CoA used for CPTI inhibition points it as an attractive candidate gene for 
disorders of energy metabolism, such as obesity and diabetes, which are characterized by an 
impaired fat oxidation. As of July 2011, the Catalog of Genome-Wide Association Studies 
(www.genome.gov/gwastudies) includes 40 studies on body mass, diabetes or type 2 diabetes. These 
studies report 192 SNPs with P values <10-5 and 147 genes. ACACB, which locates at 12q24.11, is 
not reported and the closest gene to ACACB among those reported is HNF1A, located at 12q24.31 
or approximately 11.8 Mb in the NCBI36/hg18 genome assembly. However, it cannot exclude an 
influence of ACACB variants on the risk of suffering disorders of energy metabolism. Sample size, 
inclusion of heterogeneous groups of patients and other factors may limit the power of GWAS to 
identify some genes truly related to the phenotype studied. In fact, results of other investigators 
suggested that ACACB variants could be associated with the metabolic syndrome [30] or with the 
risk of diabetic nephropathy [31;32]. In a large-scale genotyping analysis of   patients with type 2 
diabetes Maeda et al. identified found SNP rs2268388 associated with proteinuria in Japanese 
patients and with end-stage renal diseases in European Americans. As in our study, T was the risk 
allele.  In experiments with reporter vectors they found that the risk allele had higher enhancer 
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activity than the alternative allele in cultured renal cells [31] This same allele has been associated by 
Tang et al with the risk of nephropathy in Chinese diabetic patients [32]. Those studies suggest that 
that ACACB gene, and specifically rs2268388, influences the susceptibility to diabetic nephropathy 
and implicate fatty acid oxidation in the pathogenesis of this disorder. Our own results suggest that 
some allelic variants of ACACB, including those of the rs2268388 polymorphism, are indeed 
associated with severe obesity and, independently, with type 2 diabetes.  
We found that T alleles at the rs2268388 locus were much more frequent in women with severe 
obesity than in controls. Interestingly enough, the strength of association was similar to that of FTO, 
a well-recognized candidate gene for obesity [18;33-35]. However, we did not find a statistically 
significant association of ACACB alleles with BMI in the general population. These results suggest 
that ACACB variants have a stronger influence on extreme BMI than on the variation of BMI within 
the normal or moderately increased range. The explanation for this observation is unclear, but it is 
tempting to speculate that diet and other acquired factors may play a predominant role in overweight 
and mild obesity, whereas genetic factors may be the most important in severe obesity. On the other 
hand, these results  reflect the “power of extremes”, this is, the interest of studying extreme 
phenotypes when exploring the involvement of genes in common disorders [36].  
ACACB polymorphisms were also associated with type 2 diabetes mellitus. In this analysis we 
excluded women with severe obesity, who have a very high frequency of diabetes. The results were 
replicated in two independent cohorts and confirmed the association of ACACB variants with 
disorders of energy metabolism. The association of ACACB with diabetes is not surprising as an 
association of this gene with the metabolic syndrome has been reported recently [37].  The results 
presented here indicate that there is an imperfect overlapping of the SNPs associated with severe 
obesity and those associated with diabetes. This is an intriguing result because the major SNPs 
associated with either condition are only 3.0 kb apart. It is possible to speculate that changes in the 
polymorphic loci studied, or in the surrounding regions, produce subtle functional changes that in 
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turn modify ACACB activity. Since SNPs associated with obesity or diabetes are located in introns, 
the most plausible explanation is that their alleles influence ACACB gene expression. Both obesity 
and diabetes are disorders with a large environmental influence. Therefore, the lack of complete 
overlapping between the loci associated with obesity and diabetes might reflect the existence of 
regulatory elements responding to different environmental factors and causing subtle changes in 
gene expression. Interestingly, the reported association of ACACB with the metabolic syndrome 
seems to be modulated by dietary fat [37].  
Our study has some limitations. We only studied Caucasian women. Therefore, it is unclear if these 
results can be extrapolated to men or women with other ethnic background. On the other hand, we 
have limited information about dietary habits and physical activity. Therefore, we could not explore 
the potential interactions between those acquired factors and genetic factors, which clearly is an 
important subject for future studies. Candidate gene studies can have false positive results, due to 
population stratification and other causes of bias. We used various strategies to diminish this risk and 
support the validity of the associations. First, we studied women from a limited geographic area and 
excluded those with non-Spanish ancestors. Second, we used a multiple test-corrected threshold for 
statistical significance to diminish the type I error risk related to the multiple SNPs analyzed. 
Furthermore, we replicated the association of ACACB polymorphisms with type 2 diabetes in a 
different cohort of women. Unfortunately, a group of women with severe obesity was not available 
for replication. On the other hand, the association between ACACB polymorphisms, obesity and 
diabetes is plausible from a biological point of view, as discussed above. In multivariate analyses   
the association between ACACB polymorphisms and type 2 diabetes was independent of BMI. 
However, there were very few patients with diabetes and BMI<25. Therefore, we could not make a 
BMI-stratified analysis to compare the strength of association between ACACB variants and diabetes  
in overweight and lean women.  
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We also explored the potential functional consequences of the allelic changes in vitro. Although the 
study of the regulatory properties of the regions surrounding SNPs is a complex issue, we used an 
indirect approach by analyzing the changes in the protein binding properties of those DNA regions. 
Our in vitro studies demonstrated a differential binding of nuclear factors to the alleles of the major 
loci associated with obesity and diabetes. These results are in line with those by Maeda et al [31] and 
suggested a functional role of those polymorphisms.  However, as an alternative explanation, the 
association between ACACB variants and obesity/diabetes could be actually due to other true 
regulatory loci in linkage disequilibrium with those analyzed in the present study. Whether the 
polymorphisms are located in real regulatory elements or not will require further research. 
Nevertheless, bioinformatics analyses and EMSA with competing oligonucleotides suggested that 
the glucocorticoid receptor and SRF bound to the polymorphic regions of the ACACB gene. These 
results are quite interesting, in view of the well-recognized metabolic effects of glucocorticoids, and 
the recently reported influence of SRF on insulin resistance [38]. 
In summary, our results show that allelic variants of the ACACB gene are associated with severe 
obesity and with type 2 diabetes mellitus, thus adding new information to the complex genetic nature 
of those disorders. Further studies are required to elucidate the molecular mechanisms involved and 
to delineate the interactions between environmental factors and gene variants.  
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6. TABLES 
Table 1. Characteristics of women studied. 
 Discovery cohort 
(n=972) 
Morbid obesity 
(n=161) 
Replication cohort 
(n=723) 
Age, yr 66±8 59±8 57±6 
Height, cm 155±6 155±111 157±6 
Weight, kg 68±11 108±17 66±11 
BMI, kg/m2 28.3±4.4 44.7±5.8 26.7±4.3 
Diabetes, % 9.9 39.8 11.5 
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Table 2. SNPs analyzed.  
 
SNP 
Chromosome 
location 
Relative location  
(Hg18) Allele 1 Allele 2 MAF 
p-value  
HWE 
rs7969109 108054040 upstream C T 0.189 0.44 
rs1654875 108057512 upstream A T 0.242 0.74 
rs3858707 108065876 intron A G 0.367 0.52 
rs2300460 108070434 intron C T 0.169 0.46 
rs2268390 108119660 intron A G 0.193 0.34 
rs7976245 108125545 intron A G 0.385 0.62 
rs4766455 108125961 intron C G 0.161 0.91 
rs4766564 108126216 intron T A 0.431 0.47 
rs4766565 108126361 intron A G 0.161 1.00 
rs2268388 108128028 intron T C 0.117 0.04 
rs2268387 108128078 intron C T 0.458 0.86 
rs12818490 108128830 intron A G 0.275 0.00003 
rs2239608 108131105 intron G T 0.317 0.95 
rs2239607 108131663 intron C T 0.203 0.47 
rs11613533 108135607 intron T C 0.143 0.40 
rs2300452 108142453 intron T C 0.203 0.41 
rs4766584 108147964 intron G A 0.318 0.79 
rs3742026 108155040 intron G C 0.366 0.44 
rs7963249 108156432 intron A G 0.251 0.00019 
rs2241220 108159412 coding-synon T C 0.148 0.82 
rs2160602 108164386 intron T A 0.393 0.03 
rs2284689 108169928 intron T C 0.168 0.07 
rs2268385 108173429 intron C G 0.204 0.86 
rs2268384 108173776 intron G A 0.470 0.51 
rs3742023 108178365 coding-synon A G 0.417 0.71 
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Table 3. Allele and genotype frequencies of the rs2268388 polymorphism in women with morbid 
obesity and controls (general population). The odds ratio and the 95% confidence intervals are also 
shown. 
 
 
C 
% 
T 
% 
CC 
n (%) 
TC 
n (%) 
TT 
n (%) 
Cases 82.3 17.7 113 (70.2) 39 (24.2) 9 (5.6) 
Controls 89.3 10.7 778 (80.0) 180 (18.5) 14 (1.4) 
OR - - 1  
(reference) 
1.49 
 (1.00-2.22) 
4.43  
(1.87-10.46) 
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Table 4. Allele frequencies of SNPs associated with type 2 diabetes in the discovery cohort. 
Unadjusted and BMI-adjusted odds ratio (and 95% confidence intervals) and the corresponding p-
values are also shown. 
 
SNP 
Minor 
allele 
Frequency 
in cases 
Frequency 
in controls 
OR p 
Adjusted 
OR 
p 
        
rs2268388 T 0.153 0.102  1.60  
(0.99-2.57) 
0.049 1.58 
(0.99-2.52) 
0.056 
rs12818490 A 0.347 0.264 1.48  
(1.04-2.11) 
0.028 1.42 
(1.01-1.98) 
0.041 
rs2239607 C 0.289 0.194 1.69  
(1.16-2.45) 
0.005 1.70 
(1.16-2.50) 
0.006 
rs2300452 T 0.276 0.197 1.56  
(1.07-2.27) 
0.021 1.54 
(1.05-2.26) 
0.026 
rs2160602 T 0.316 0.404 0.68  
(0.48-0.97) 
0.034 0.69 
(0.49-0.98) 
0.039 
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Table 5. Genotype frequencies in patients with type 2 diabetes and controls in the discovery and 
replication cohorts. The Mantel-Haenszel adjusted odds ratio (OR), considering the most frequent 
genotypes as the reference, and the p-values for trend are also shown. 
 
 
Discovery cohort Replication cohort 
Combined 
OR 
p 
 Cases, % Controls, % Cases, % Controls, %   
rs2268388       
TT 2.7 1.4 4.3 0.7 3.6 (1.3-10.2) 0.012 
TC 25.3 17.5 22.9 20.9 1.4 (0.9-2.1)  
CC 72.0 81.1 72.8 78.4 1  
rs2239607       
CC 8.9 3.4 8.3 3.1 2.9 (1.5-5.6) 0.018 
CT 34.3 32.2 26.4 33.5 1.2 (0.8-1.7)  
TT 56.8 64.4 65.3 63.5 1  
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7. FIGURE LEGENDS 
 
Figure 1. Linkage disequilibrium map and haplotypic blocks. 
 
Figure 2. Association between ACACB polymorphisms and severe obesity in the discovery cohort. 
The association of the FTO polymorphism is also shown for comparison. 
 
Figure 3. Electrophoretic shift mobility assays (EMSA) with oligonucleotide probes for the regions 
of polymorphisms rs2268388 (A) and rs2239607 (B). The binding of nuclear proteins to 
fluorochrome-labelled probes with the sequence of each allele, in the absence or presence of excess 
unlabelled nucleotide is shown. Control lanes in absence of nuclear extracts are also shown. The 
graphs represent the inverse of band intensity versus unlabelled competitor; thus, the slope is 
inversely related to the oligonucleotide-protein binding affinity.  
 
Figure 4. EMSA with a labelled probe for the rs2268388 region and competition with a 20-fold 
excess of an unlabelled oligonucleotide containing the GR binding site (left) or with a labeled probe 
for the rs2239607 region and competition with an unlabelled oligonucleotide containing the SRF 
binding site (right).  NE, no protein extract;  E, protein extract from HepG2 cultures was added to 
the mix; X20, a 20-fold excess of an GR or SRF binding site oligonucleotide added to the reaction.  
The retarded band is pointed with an arrow. 
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